The advent of targeted therapy in oncology has revolutionized the approach to cancer treatment, promising improved patient outcomes and minimized side effects. By focusing on specific molecular and genetic alterations in cancer cells, targeted therapies offer a more personalized and effective treatment strategy.
Targeted therapies work by inhibiting or enhancing specific biological pathways that are dysregulated in cancer cells. They can be categorized into two main types: small molecules that can penetrate the cell membrane to interact with intracellular targets, and larger molecules or monoclonal antibodies that bind to specific targets on the cell surface. These therapies are designed to interfere with cellular processes that promote cancer growth, such as cell proliferation, survival, angiogenesis, and metastasis.
Compared to conventional chemotherapy, targeted therapies offer several advantages. They are more selective for cancer cells, reducing damage to healthy tissues and minimizing side effects. Moreover, they can be used in combination with other treatments to enhance efficacy. Some targeted therapies can also overcome resistance to traditional chemotherapeutic agents, offering hope for patients with refractory or relapsed disease.
Despite the promise of targeted therapies, challenges remain. These include the development of resistance, the need for precise patient selection based on molecular profiling, and the high cost of these therapies. Future research should focus on overcoming these obstacles, as well as developing novel targeted agents and identifying new therapeutic targets.
Targeted therapy represents a significant leap forward in oncology, offering a more precise and personalized approach to cancer treatment. While challenges remain, ongoing research and development hold the promise of further advancements in this field, potentially transforming the landscape of oncology treatment and improving patient outcomes.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation